Description of the Immune Response to Yellow Fever Vaccination

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorInstitut Pasteur

About this trial

Vaccine protection depends on a specific adaptive immune memory. However, a little-explored aspect of certain live vaccines may provide beneficial, non-specific protection against infections or pathogens other than the one from which the vaccine is derived. This is the concept of innate immune memory or " trained immunity", which differs from adaptive memory in its non-specificity. Innate immune memory is triggered by exposure to immunostimulants, and offers protection against unrelated pathogenic threats for several months or even years.

The project aims to carry out an exploratory study to observe, in the context of current practice, the immune response obtained after a subunit and a live attenuated vaccine

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age between 18 and 65

Referred for immunisation against yellow fever and typhoid

Yellow fever

Typhoïd

Disqualifiers

Anyone with a contraindication to yellow fever and/or typhoid vaccination.

Any person who has been vaccinated against yellow fever and/or typhoid.

Anyone who has lived in an endemic area (≥ 1 year) and/or has a history of Typhoid.

Anyone who is unable to attend the visit 1-month after the typhoid vaccine injection.

Trial design

Design model

Single group

Treatments tested in this trial

  • blood samples collection

    Biological/Vaccine

    blood samples collected at D0 ,W1, W5, M3 and M6

Treatment groups

38 Participants
are divided into 1 treatment group
Group A: People with an indication for primary immunization against yellow fever and typhoidOther 1 intervention

Trial outcomes

Primary outcomes

1

Immunological profile of PBMCs, before and after yellow fever vaccination

Cytokine production assays (e.g. TNFa, IL6, IL1b)

Time frame
6 months

Secondary outcomes

1

Description of the response to TyphimVi® vaccine

ELISA-based quantification of Anti-Vi antibody level \>30 U/mL at week 5, and/or fold increase ≥2 compared with pre-vaccination IgG titer.

Time frame
6 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.